Revenue cycle · Generative AI automation
AKASA
AKASA is a generative AI product for health-system revenue cycle teams. It targets prior auth, coding assist, and other high-touch RCM work where denials and manual touches are measurable. It is not a clearinghouse or a full claims platform by itself.
Strong fit
- Health systems automating prior auth, coding assist, or other RCM workflows with measurable denial and touch metrics
- Teams that can feed clean EHR and payer data into automation and staff exception queues
- Leaders who will retire manual steps when automation holds, not run dual processes forever
Weak fit
- Organizations with chaotic payer and EHR data and no RCM ops owner
- Buyers seeking a full clearinghouse replacement like Waystar
- Groups that will not change coder or prior-auth staffing models after go-live
Bottom line
AKASA earns a Recommend for revenue-cycle teams buying generative AI automation against specific denial, prior-auth, or coding bottlenecks. Outcomes look strongest when touch-time and denial metrics are owned before the pilot. Product focus is automation on top of existing RCM stacks rather than replacing Waystar-style claims infrastructure. Implementation is data and change-management heavy. Pricing is enterprise-opaque. Score sits with Availity on our revenue-cycle board and below Waystar's broader claims platform mark.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
AKASA sells generative AI automation for revenue-cycle work such as prior authorization and related back-office workflows. It is not a clearinghouse substitute. Diligence should compare it to outcome metrics on your queues, not to Waystar's claims footprint.
Pilots that keep every manual step "just in case" rarely show ROI. Pilots that redesign exception queues and retire duplicate touches have a clearer path.
Score reflects solid automation product and outcomes marks for mid-to-large RCM buyers, with implementation and pricing clarity in the ordinary enterprise range for this station.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| AKASA | 7.5 | 7.0 |
| Waystar | 8.0 | 7.7 |
| Availity | 7.5 | 7.3 |
| Experian Health | 7.0 | 6.7 |
Pricing
| Item | Detail |
|---|---|
| Model | Enterprise subscription for AI automation modules; multi-year agreements are common. |
| What usually drives cost | Workflow modules in scope, transaction or FTE baselining, and professional services. |
| What to ask in diligence | Modeled savings on your target prior-auth or coding queue with data readiness listed explicitly. |
| Published pricing | Public list price: not published. Expect a custom quote; confirm total cost at your volume. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get AKASA to function | |
| A named RCM ops owner for the target queue (prior auth, coding, etc.) | Automation without an ops owner never retires manual work. |
| Workable EHR and payer data for the pilot workflows | Garbage inputs create noisy AI exceptions. |
| Staffed exception queues after automation | Unhandled exceptions recreate backlog. |
| Willingness to redesign desk steps when automation holds | Dual processes erase ROI. |
| Baseline touch-time and denial metrics before go-live | You cannot prove value without a baseline. |
| What will maximize your value | |
| Pick one bottleneck workflow for the first wave | Multi-queue pilots dilute learning. |
| Retire duplicate manual steps on a written schedule | Forever-pilots never show savings. |
| Review exception themes weekly with coding or auth leads | Model drift and payer rules change. |
| Tie vendor success fees or renewals to your metrics | Keep commercial pressure aligned to outcomes. |
| Document payer-specific failure modes | National averages hide your mix. |
| Deal-breakers | |
| You need a clearinghouse replacement (Waystar-shaped buy). | |
| No RCM ops owner will redesign staffing after go-live. | |
| Source data for the target queue is chaotic with no remediation plan. | |
| Leadership will keep full dual processes indefinitely. | |
| IT cannot support integrations for the next two quarters. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Contract signed → kickoff | 3–8 weeks (security, SOW, data access, baseline metrics) |
| 2 | Kickoff → first live workflow | 10–20 weeks for a first production automation workflow |
| 3 | First live workflow → steady value | 3–6 months of exception tuning before adding queues |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.